Asian shares looked set to open lower on Tuesday as investors shifted focus to upcoming data and central bank meetings although positive developments around potential Covid-19 vaccines and increased deal activity are likely to stem losses.
Australia’s S&P/ASX 200 futures were down 0.22 per cent and Hong Kong’s Hang Seng index futures lost 0.08 per cent. Japan’s Nikkei 225 futures were flat after Chief Cabinet Secretary Yoshihide Suga won a ruling party leadership election, paving the way for him to succeed Prime Minister Shinzo Abe.
E-mini futures for the S&P 500 gained 0.11 per cent.
On the economic data front, China’s industrial production and retail sales for August are expected to show an improving economy later on Tuesday. Chinese house price data for August is also due.
“The global economic recovery is currently being driven by China’s fast rebound,” said Joseph Capurso, head of international economics at Commonwealth Bank of Australia. “As a result, market participants will likely be very sensitive to any downside surprises to the Chinese data.”
US retail sales figures from August are due Wednesday.
Investors will also look to central banks for direction, with the US Federal Reserve starting a two-day policy meeting on Tuesday, the first since unveiling a landmark shift to a more tolerant stance on inflation in August. The Bank of Japan and the Bank of England announce their respective policy decisions on Thursday.
MSCI’s broadest index of Asia-Pacific shares outside Japan ended up 1.06 per cent.
The Dow Jones Industrial Average closed up 1.18 per cent and the S&P 500 rose 1.27 per cent while the tech-heavy Nasdaq Composite added 1.87 per cent.
US stocks rose after drugmaker AstraZeneca said it resumed its British clinical trials of its Covid-19 vaccine, one of the most advanced in development. Pfizer Inc and US-listed shares of Germany’s BioNTech gained after proposing an